GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » uniQure NV (NAS:QURE) » Definitions » Cyclically Adjusted Price-to-FCF

uniQure NV (uniQure NV) Cyclically Adjusted Price-to-FCF : (As of Jun. 10, 2024)


View and export this data going back to 2014. Start your Free Trial

What is uniQure NV Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


uniQure NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for uniQure NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

uniQure NV Cyclically Adjusted Price-to-FCF Chart

uniQure NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

uniQure NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of uniQure NV's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, uniQure NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


uniQure NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where uniQure NV's Cyclically Adjusted Price-to-FCF falls into.



uniQure NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

uniQure NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, uniQure NV's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.3/128.5800*128.5800
=-1.300

Current CPI (Mar. 2024) = 128.5800.

uniQure NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.975 99.240 -1.263
201409 -0.710 99.960 -0.913
201412 -1.016 99.050 -1.319
201503 -0.832 99.750 -1.072
201506 1.952 100.230 2.504
201509 -0.080 100.500 -0.102
201512 -1.054 99.730 -1.359
201603 -0.712 100.310 -0.913
201606 -0.974 100.260 -1.249
201609 -1.091 100.570 -1.395
201612 -0.789 100.710 -1.007
201703 -0.536 101.440 -0.679
201706 -0.805 101.370 -1.021
201709 -0.639 102.030 -0.805
201712 -0.615 101.970 -0.775
201803 -0.697 102.470 -0.875
201806 -0.512 103.100 -0.639
201809 -0.562 103.950 -0.695
201812 -0.502 103.970 -0.621
201903 -0.734 105.370 -0.896
201906 -0.672 105.840 -0.816
201909 -0.596 106.700 -0.718
201912 -0.640 106.800 -0.771
202003 -0.809 106.850 -0.974
202006 -0.714 107.510 -0.854
202009 -0.830 107.880 -0.989
202012 -0.891 107.850 -1.062
202103 -0.993 108.870 -1.173
202106 8.825 109.670 10.347
202109 -1.037 110.790 -1.204
202112 -1.077 114.010 -1.215
202203 -0.639 119.460 -0.688
202206 -0.434 119.050 -0.469
202209 -1.133 126.890 -1.148
202212 -1.274 124.940 -1.311
202303 -1.700 124.720 -1.753
202306 -1.219 125.830 -1.246
202309 0.779 127.160 0.788
202312 -1.079 126.450 -1.097
202403 -1.300 128.580 -1.300

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


uniQure NV  (NAS:QURE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


uniQure NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of uniQure NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


uniQure NV (uniQure NV) Business Description

Industry
Traded in Other Exchanges
Address
Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Executives
Walid Abi-saab officer: Chief Medical Officer C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 11058BP
Ricardo Dolmetsch officer: President, R&D 113 HARTWELL AVENUE, LEXINGTON MA 02421
Pierre Caloz officer: Chief Operating Officer UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM P7 P7 11058BP
Madhavan Balachandran director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rachelle Suzanne Jacques director C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Robert Gut director C/O VERSARTIS, INC., 4200 BOHANNON DRIVE, SUITE 250, MENLO PARK CA 94025
Leonard E Post director
Christian Klemt officer: Chief Financial Officer PAASHEUVELWEG 25A, AMSTERDAM P7 1105 BP
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Jeremy P. Springhorn director C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
David D. Meek director 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Matthew C Kapusta director, officer: CEO, Managing Director 7358 MCVAY ROAD, GERMANTOWN TN 38138
Kuta Alexander Edward Iii officer: Executive VP, Operations 239 WILLIS ROAD, SUDBURY MA 01776

uniQure NV (uniQure NV) Headlines

From GuruFocus